Transaction complements Tempest’s existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned ...

CD7 gene-edited chimeric antigen receptor (CAR) T cells target CD7-positive acute myeloid leukemia (AML) cells while sparing myeloid and erythroid cells and minimizing toxicity, according to the ...

This study introduces a novel "all-in-one" strategy combining CD7 chimeric antigen receptor T-cell therapy with haploidentical hematopoietic stem-cell transplantation, showing significant potential to ...

For patients with relapsed or refractory CD7-positive leukemia or lymphoma, sequential CD7 chimeric antigen receptor (CAR) T-cell therapy followed by haploidentical hematopoietic stem-cell ...

Tempest Therapeutics ( TPST ), a clinical-stage biotechnology company developing in vivo CAR-T therapies for cancer and autoimmune disease, announced an exclusive option agreement with Hebei Senlang ...

CD7 expression is associated with poorer outcomes in patients with newly diagnosed acute myeloid leukemia (AML), according to a study published online April 11 in the British Journal of Haematology.

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome Twenty participants ...

Researchers have reported that CD7 may be a viable CAR T-cell target in a subset of relapsed/refractory acute myeloid leukemia, and that fratricide-resistant CD7 CAR T cells can induce deep remissions ...

A strategy of sequential CD7 chimeric antigen receptor (CAR) T-cell therapy and haploidentical hematopoietic stem-cell transplantation (HSCT), without graft-versus-host disease (GVHD) prophylaxis, is ...